Enveric Biosciences Announces Stock Offering Plan
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 17 2026
0mins
Source: seekingalpha
- Offering Details: Enveric Biosciences has announced the sale of 2.22 million shares of common stock or pre-funded warrants, along with Series I and short-term Series J warrants at $2.25 per share, expecting total gross proceeds of approximately $5 million, indicating the company's proactive approach to capital raising.
- Warrant Potential: If fully exercised, the Series I and Series J warrants could add about $8.9 million more, although there is no guarantee of their exercise, reflecting the company's cautious stance on future financing.
- Use of Proceeds: The net proceeds from this offering will be allocated for product development, working capital, and general corporate purposes, demonstrating the company's strategic intent to drive business growth and innovation.
- Expected Closing Date: The offering is anticipated to close around April 17, 2026, indicating the company's strategic timing and planning for future developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ENVB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ENVB
About ENVB
Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The Company is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump's Executive Order Accelerates Psychedelic Drug Development
- Investor Capital Influx: Trump's executive order has sparked interest among investors in psychedelic drug development companies, with Enveric Biosciences raising $5 million following the announcement, indicating heightened market attention despite researchers cautioning that new treatments are still far from realization.
- Improved FDA-DEA Coordination: Nine executives and investors noted that the order could shorten administrative timelines and enhance coordination between the FDA and DEA, potentially saving clinical-stage companies tens of millions in costs and improving overall research efficiency.
- Reduced Regulatory Uncertainty: Sa'ad Shah, co-founder of Noetic Fund, highlighted that the executive order may attract institutional investors like sovereign wealth funds and public pension plans into the psychedelic sector, alleviating previous regulatory uncertainties and signaling credible government backing for the industry.
- Accelerated Development Processes: Robert Barrow, CEO of Definium Therapeutics, stated that the implementation of the order will streamline regulatory processes, particularly allowing the DEA to begin scheduling controlled substances after FDA approval, which will facilitate faster market access for psychedelic drugs.
See More
Enveric Biosciences Reports Q1 Financial Results
- Financial Performance: Enveric Biosciences reported a Q1 GAAP EPS of -$1.08, indicating challenges in profitability that may affect investor confidence and lead to stock price volatility.
- Cash Position: As of March 31, 2026, the company had $4.9 million in cash on hand, reflecting tight liquidity that could limit future R&D and operational activities.
- Funding Activities: During the quarter, the company raised gross proceeds of $2.8 million through offerings, providing short-term funding support, yet still insufficient to cover ongoing operational losses.
- Future Funding Goals: Enveric Biosciences aims to raise up to $13.9 million through share and warrant offerings, a strategy that may help improve financial conditions but could also dilute existing shareholders' equity.
See More
Lakewood-Amedex Appoints New Board Member to Strengthen Governance
- Board Enhancement: Lakewood-Amedex Biotherapeutics has appointed Dr. Joseph Tucker to its Board of Directors, a move aimed at strengthening the company's governance capabilities, particularly following its recent direct listing on Nasdaq to enhance strategic decision-making.
- Rich Industry Experience: Dr. Tucker brings over 20 years of leadership experience in biotechnology, having served as CEO in multiple companies and successfully driving various financings and clinical programs, which is expected to provide valuable market insights for the company.
- Product Development Outlook: The company is developing its Nu-3 product for infected diabetic foot ulcers, which has the potential for rapid elimination of a broad spectrum of bacteria, with upcoming clinical trials set to further validate its safety and efficacy.
- Capital Market Strategy: Dr. Tucker's addition is viewed as a crucial step in accelerating the company's growth strategy, especially given his background of raising over $100 million in funding, which is expected to support future financing and market expansion efforts.
See More
Lakewood-Amedex Appoints New Board Member to Strengthen Governance
- Board Enhancement: Lakewood-Amedex Biotherapeutics has appointed Dr. Joseph Tucker to its Board of Directors, a move aimed at strengthening the company's governance capabilities to support its growth strategy following its recent Nasdaq listing.
- Rich Industry Experience: Dr. Tucker brings over 20 years of leadership experience in biotechnology, having served as CEO in multiple companies, successfully driving strategic financings and clinical programs, which is expected to provide valuable market insights for the company.
- Product Development Outlook: The company's Nu-3 product targets infected diabetic foot ulcers and has the potential to rapidly eliminate a broad spectrum of bacteria, expected to fill a significant gap in the market for antibiotic resistance treatments.
- Clinical Trial Plans: Based on initial clinical trial results, Lakewood-Amedex plans to conduct a Phase 2a safety and dose response study for Nu-3, further validating its efficacy in treating infected diabetic foot ulcers.
See More
U.S. Stocks Rally with Tech Gains, Near All-Time Highs
- Market Performance: The S&P 500 rose about 0.8% and the Nasdaq Composite increased by 1.63%, marking the fourth consecutive week of gains, driven by strong corporate earnings and policy support, reflecting robust investor confidence in tech stocks.
- Cannabis Sector Surge: Akanda Corp. (AKAN) shares skyrocketed over 300% this week after the Trump administration advanced plans to reclassify marijuana as a Schedule III drug, with single-day gains reaching 214%, igniting a rally across the cannabis sector.
- Strong Semiconductor Earnings: MaxLinear (MXL) shares surged more than 75% after reporting a 43% year-over-year revenue increase and raising guidance, highlighting robust demand for its optical and connectivity chips in AI data centers, showcasing the company's strong market position.
- Psychedelic Drug Development: Enveric Biosciences (ENVB) shares jumped over 100% following Trump's executive order to accelerate research and approval for psychedelic therapies, marking the company's best week ever and reflecting optimistic market sentiment towards mental health drug development.
See More
FDA Accelerates Development of Psychedelic Treatments for Mental Health
- Regulatory Push: The FDA has announced plans to accelerate the development of psychedelic treatments to address serious mental health issues, particularly post-traumatic stress disorder and treatment-resistant depression, indicating strong support for innovative therapies.
- Presidential Directive: Last week, President Trump signed an executive order directing health agencies to expedite research on psychedelic substances like psilocybin, MDMA, and ibogaine, aiming to swiftly tackle the national mental health crisis, especially for veterans.
- Market Reaction: Following the FDA's new policy, shares of Compass Pathways Plc. (CMPS), Helus Pharma Inc. (HELP), and Enveric Biosciences Inc. (ENVB) rose between 2% and 7% in Friday's opening trade, reflecting investor optimism about the psychedelic drug market's potential.
- Industry Outlook: This FDA initiative not only paves the way for clinical applications of psychedelics but may also encourage more companies to enter this emerging market, thereby driving innovation and growth among related firms.
See More
Trump's Executive Order Accelerates Psychedelic Drug Development
- Investor Capital Influx: Trump's executive order has sparked interest among investors in psychedelic drug development companies, with Enveric Biosciences raising $5 million following the announcement, indicating heightened market attention despite researchers cautioning that new treatments are still far from realization.
- Improved FDA-DEA Coordination: Nine executives and investors noted that the order could shorten administrative timelines and enhance coordination between the FDA and DEA, potentially saving clinical-stage companies tens of millions in costs and improving overall research efficiency.
- Reduced Regulatory Uncertainty: Sa'ad Shah, co-founder of Noetic Fund, highlighted that the executive order may attract institutional investors like sovereign wealth funds and public pension plans into the psychedelic sector, alleviating previous regulatory uncertainties and signaling credible government backing for the industry.
- Accelerated Development Processes: Robert Barrow, CEO of Definium Therapeutics, stated that the implementation of the order will streamline regulatory processes, particularly allowing the DEA to begin scheduling controlled substances after FDA approval, which will facilitate faster market access for psychedelic drugs.
See More
Enveric Biosciences Reports Q1 Financial Results
- Financial Performance: Enveric Biosciences reported a Q1 GAAP EPS of -$1.08, indicating challenges in profitability that may affect investor confidence and lead to stock price volatility.
- Cash Position: As of March 31, 2026, the company had $4.9 million in cash on hand, reflecting tight liquidity that could limit future R&D and operational activities.
- Funding Activities: During the quarter, the company raised gross proceeds of $2.8 million through offerings, providing short-term funding support, yet still insufficient to cover ongoing operational losses.
- Future Funding Goals: Enveric Biosciences aims to raise up to $13.9 million through share and warrant offerings, a strategy that may help improve financial conditions but could also dilute existing shareholders' equity.
See More
Lakewood-Amedex Appoints New Board Member to Strengthen Governance
- Board Enhancement: Lakewood-Amedex Biotherapeutics has appointed Dr. Joseph Tucker to its Board of Directors, a move aimed at strengthening the company's governance capabilities, particularly following its recent direct listing on Nasdaq to enhance strategic decision-making.
- Rich Industry Experience: Dr. Tucker brings over 20 years of leadership experience in biotechnology, having served as CEO in multiple companies and successfully driving various financings and clinical programs, which is expected to provide valuable market insights for the company.
- Product Development Outlook: The company is developing its Nu-3 product for infected diabetic foot ulcers, which has the potential for rapid elimination of a broad spectrum of bacteria, with upcoming clinical trials set to further validate its safety and efficacy.
- Capital Market Strategy: Dr. Tucker's addition is viewed as a crucial step in accelerating the company's growth strategy, especially given his background of raising over $100 million in funding, which is expected to support future financing and market expansion efforts.
See More
Lakewood-Amedex Appoints New Board Member to Strengthen Governance
- Board Enhancement: Lakewood-Amedex Biotherapeutics has appointed Dr. Joseph Tucker to its Board of Directors, a move aimed at strengthening the company's governance capabilities to support its growth strategy following its recent Nasdaq listing.
- Rich Industry Experience: Dr. Tucker brings over 20 years of leadership experience in biotechnology, having served as CEO in multiple companies, successfully driving strategic financings and clinical programs, which is expected to provide valuable market insights for the company.
- Product Development Outlook: The company's Nu-3 product targets infected diabetic foot ulcers and has the potential to rapidly eliminate a broad spectrum of bacteria, expected to fill a significant gap in the market for antibiotic resistance treatments.
- Clinical Trial Plans: Based on initial clinical trial results, Lakewood-Amedex plans to conduct a Phase 2a safety and dose response study for Nu-3, further validating its efficacy in treating infected diabetic foot ulcers.
See More
U.S. Stocks Rally with Tech Gains, Near All-Time Highs
- Market Performance: The S&P 500 rose about 0.8% and the Nasdaq Composite increased by 1.63%, marking the fourth consecutive week of gains, driven by strong corporate earnings and policy support, reflecting robust investor confidence in tech stocks.
- Cannabis Sector Surge: Akanda Corp. (AKAN) shares skyrocketed over 300% this week after the Trump administration advanced plans to reclassify marijuana as a Schedule III drug, with single-day gains reaching 214%, igniting a rally across the cannabis sector.
- Strong Semiconductor Earnings: MaxLinear (MXL) shares surged more than 75% after reporting a 43% year-over-year revenue increase and raising guidance, highlighting robust demand for its optical and connectivity chips in AI data centers, showcasing the company's strong market position.
- Psychedelic Drug Development: Enveric Biosciences (ENVB) shares jumped over 100% following Trump's executive order to accelerate research and approval for psychedelic therapies, marking the company's best week ever and reflecting optimistic market sentiment towards mental health drug development.
See More
FDA Accelerates Development of Psychedelic Treatments for Mental Health
- Regulatory Push: The FDA has announced plans to accelerate the development of psychedelic treatments to address serious mental health issues, particularly post-traumatic stress disorder and treatment-resistant depression, indicating strong support for innovative therapies.
- Presidential Directive: Last week, President Trump signed an executive order directing health agencies to expedite research on psychedelic substances like psilocybin, MDMA, and ibogaine, aiming to swiftly tackle the national mental health crisis, especially for veterans.
- Market Reaction: Following the FDA's new policy, shares of Compass Pathways Plc. (CMPS), Helus Pharma Inc. (HELP), and Enveric Biosciences Inc. (ENVB) rose between 2% and 7% in Friday's opening trade, reflecting investor optimism about the psychedelic drug market's potential.
- Industry Outlook: This FDA initiative not only paves the way for clinical applications of psychedelics but may also encourage more companies to enter this emerging market, thereby driving innovation and growth among related firms.
See More
